Eli Lilly的新药片帮助体重超重的成年人 患2型糖尿病的人 失去体重的10.5%, 提升公司股份。 Eli Lilly's new pill helps overweight adults with type 2 diabetes lose 10.5% of their weight, boosting company shares.

Eli Lilly的实验性GLP-1药片,或者说Forglipron,在后期试验中显示出显著体重下降的结果,帮助2型糖尿病的超重成年人平均体重损失10.5%。 Eli Lilly's experimental GLP-1 pill, orforglipron, showed significant weight loss results in a late-stage trial, helping overweight adults with type 2 diabetes lose an average of 10.5% of their body weight. 药丸的性能与诺沃诺迪斯克的Wegovy相比具有竞争力,结果使莉莉的股份增加了近4%。 The pill's performance is competitive with Novo Nordisk's Wegovy, and the results have boosted Lilly's shares by nearly 4%. 尽管药片有恶心和呕吐等副作用,但药片也改善了心脏健康标记,其全球最高销售额估计达到147亿美元。 Despite side effects like nausea and vomiting, the pill also improved heart health markers, and its global peak sales are estimated to reach $14.7 billion.